Search the Newsreel

Coca-Cola Europacific Partners GAAP EPS of €2.17, revenue of €10.72B

* Coca-Cola Europacific Partners press release [https://seekingalpha.com/pr/20605059-coca-cola-europacific-partners-plc-announces-results-for-the-six-months-ended-3-july-2026] (CCEP [https://seekingalpha.com/symbol/CCEP]): 1H GAAP EPS of €2.17 * Revenue of €10.72B (+4.4% Y/Y). * FY26 guidance reaffirmed: * Revenue: Growth of 3% to 4% on a comparable and FX-neutral basis. Current spot rates imply an FX headwind …

Royal Bank of Canada Lowers Stock Holdings in Euronet Worldwide, Inc. $EEFT

Royal Bank of Canada decreased its stake in Euronet Worldwide (NASDAQ:EEFT) by 33.8% in the first quarter, selling over 246,000 shares but still retaining 482,151 shares valued at $32 million. Despite this reduction, institutional investors collectively hold 91.6% of EEFT, and other major institutions …

NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has received a "Moderate Buy" consensus recommendation from ten analysts, with an average 12-month price target of $19.29, significantly above its recent opening price of $13.50. The company recently surpassed earnings expectations, reporting a smaller adjusted loss and higher revenue than …

ClearPoint Neuro outlines $48M-$52M 2026 revenue guidance as it prioritizes CAL, clinical capacity, and focused ultrasound partnership

Earnings Call Insights: ClearPoint Neuro (CLPT) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 in itself has been an exciting one and possibly one of the most important series of events in our history," said Joseph Burnett (President, CEO & Director), adding …

ClearPoint Neuro (Nasdaq: CLPT) grows Q2 revenue and updates 2026 outlook

ClearPoint Neuro (CLPT) reported strong Q2 2026 revenue of $10.9 million, an 18% increase year-over-year, driven by significant growth in neurosurgery navigation and therapy. The company has updated its 2026 revenue guidance to between $48.0 million and $52.0 million, reflecting strategic investments in clinical …

Coca-Cola Europacific tops Q2 estimates on profit, revenue; shares slip premarket

Coca-Cola Europacific Partners (CCEP) exceeded Q2 profit and revenue estimates due to higher volumes and pricing in Europe and Asia-Pacific, with profit after taxes rising 5.8% to €991 million and revenue increasing 4.4% to €10.72 billion. Despite the strong performance, shares dipped 3.6% in …

Coca-Cola Europacific Partners (CCEP) Posts €10.7bn H1 Revenue, Reaffirms 2026 Full-Year Outlook

Earnings Flash (CCEP.L) Coca-Cola Europacific Partners plc Posts H1 EPS EUR2.17

Coca-Cola Europacific Partners gana 991 millones hasta junio (+5,8%) y reitera previsiones

Janus Henderson Group PLC Increases Stock Position in Minerva Neurosciences, Inc $NERV

Coca-Cola Europacific Partners (NASDAQ:CCEP) Announces Quarterly Earnings Results

Coca-Cola Europacific Partners PLC (CCEP) Earnings Date & Reports & Earnings News

Coca-Cola Europacific Partners PLC 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CCEP) 2026-08-04

Economía/Bolsa.- Las acciones de Coca-Cola Europacific Partners caen un 5,45% pese a ganar un 5,8% en el primer semestre

More than 80,000 new coolers added in Coca-Cola Europacific's H1

Earnings Flash (CCEP.L) Coca-Cola Europacific Partners Reports H1 Revenue EUR10.72B

Coca-Cola Europacific Partners plc Announces Results for The Six Months Ended 3 July 2026

UXBRIDGE, ENGLAND / ACCESS Newswire / August 4, 2026 / Strong first half performance; full-year guidance reaffirmed H1 2026 Total CCEP Key Financial Metrics[1] As Reported Comparable [1] Change vs H1 2025 As Reported Comparable [1] Comparable FXN [1] Volume (M UC)[2] 2,041 2,041 …

Entropy Neurodynamics Gains Ethics Approval for Eight-Indication TRP-8803 Trial

Kaskela Law Firm Announces Stockholder Investigation of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) and Encourages Long-Term JUNS Investors to Contact the Firm

Kaskela Law LLC has initiated an investigation into Jupiter Neurosciences, Inc. (NASDAQ:JUNS) on behalf of its shareholders. The firm is looking into whether Jupiter and its officers/directors violated securities laws or breached fiduciary duties. Long-term JUNS investors are encouraged to contact Kaskela Law LLC …

Neuronetics shareholder Chernett seeks board seat in push to maximize shareholder value

Neuronetics has reached an agreement with its second-largest shareholder, Jorey Chernett, regarding board representation. Chernett, an activist shareholder, will recommend a new director and has expressed support for the company's management following discussions on its financial health and capital optimization. This development comes as …

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Alto Neuroscience, Inc. (ANRO)

Levi & Korsinsky LLP has filed a class action lawsuit against Alto Neuroscience, Inc. (ANRO) on behalf of investors who suffered losses. The lawsuit alleges that Alto Neuroscience made false and misleading statements regarding the effectiveness of its product pipeline, ALTO-100, for treating major …

Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts

Eleven analysts have given Alto Neuroscience, Inc. (NYSE:ANRO) a consensus "Moderate Buy" rating, with eight recommending a buy, two a sell, and one a hold. The average 12-month price target is $35.25, significantly higher than its opening price of $27.09. Despite increased institutional investment …

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.29 loss, and revenues of $10.88 million, falling short of estimates by 16.31%. The company's shares have gained 9.2% year-to-date, slightly underperforming the S&P 500. …

Minerva Neurosciences (NERV) awards options tied to Phase 3 trial

Minerva Neurosciences (NERV) reported the grant of 12,147 stock options to director Inderjit Kaul, with an exercise price of $3.97 and an expiration date of August 2, 2036. The options' vesting is performance- and time-based, with significant portions contingent on the success of a …

Form 4 Minerva Neurosciences Inc For: 3 August By Investing.com

This article announces the filing of a Form 4 for Minerva Neurosciences Inc. on August 3rd. It indicates that this is an insider trading report, suggesting that company insiders have bought or sold shares. The article also provides the stock's current performance (NERV +2.02%).

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro (CLPT) reported an 18% revenue growth in Q2 2026, reaching $10.9 million, and adjusted its full-year guidance to $48-$52 million. The company is shifting investment priorities towards clinical capacity, preclinical laboratory services, and neuro drug delivery technologies, with increased spending in R&D, …

ProMIS Neurosciences to report Q2 results, host investor call and webcast

ProMIS Neurosciences will release its Q2 results for the period ending June 30, 2026, on August 13, 2026. The company will also host an investor conference call and webcast on the same day at 4:30 p.m. ET to discuss the results. This news brief …

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings

ClearPoint Neuro, Inc. (CLPT) reported its Q2 2026 earnings, missing analyst expectations for both EPS and revenue. The company's cash reserves decreased, and it lowered its full-year 2026 revenue guidance to $48 million to $52 million. This performance is attributed to a pivot towards …

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro, Inc. announced its second-quarter 2026 financial results, reporting $10.9 million in revenue, an 18% increase year-over-year, driven by the IRRA flow Portfolio acquisition and growth in neurosurgery navigation. While Biologics and Drug Delivery revenue saw a decline, the company expects a rebound …

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

ProMIS Neurosciences Inc. will report its second-quarter 2026 financial results and provide a corporate update on August 13, 2026. The company will host an investor conference call and webcast on the same day at 4:30 p.m. ET to discuss these results and updates. ProMIS …

889,254 Shares in Minerva Neurosciences, Inc $NERV Bought by DV Trading LLC

DV Trading LLC purchased 889,254 shares of Minerva Neurosciences (NASDAQ:NERV) during the first quarter, making the biopharmaceutical company its 10th largest holding. Several other institutions also increased their stakes, leading to 34.56% institutional ownership. Despite increased institutional interest, analysts maintain a "Hold" rating with …

Canaccord raises Neurocrine Bio price target on strong sales beat

Canaccord Genuity increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) from $200 to $210, maintaining a Buy rating, following the company's strong second-quarter performance. Neurocrine's sales for Ingrezza and Crenessity significantly exceeded analyst estimates, contributing to a 34% revenue growth. The company …

(CLPT) as a Liquidity Pulse for Institutional Tactics

Clearpoint Neuro, Inc. (NASDAQ: CLPT) is experiencing strong near-term sentiment that is challenging persistent mid and long-term weakness. The article details institutional trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis, indicating potential resistance and support levels. An exceptional 117.8:1 …

Eurofins: Weekly Report on Share Repurchases From 27th July to 31st July 2026

LUXEMBOURG, August 03, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS …

Jupiter Neurosciences expands into psychedelics with $100m deal

Jupiter Neurosciences has acquired exclusive US rights to ALA-002, a clinical-stage psychedelic therapy candidate, for up to $100 million, marking its expansion into neuropsychiatric disorders. This move adds a second clinical program to Jupiter's portfolio, alongside therapies for Parkinson's disease, and signals a broader …

Stoneweg Europe Stapled Trust sets 1H 2026 results briefing as it doubles down on logistics and data centres